The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-09-18
DOI
10.3389/fimmu.2020.01721
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CheckMate 141 trial: all that glitters is not gold
- (2019) Raffaele Addeo et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Histoepigenetic analysis of HPV- and tobacco-associated head and neck cancer identifies both subtype-specific and common therapeutic targets despite divergent microenvironments
- (2019) Ivenise Carrero et al. ONCOGENE
- Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma
- (2019) Julius Moratin et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort
- (2019) Neil H. Segal et al. EUROPEAN JOURNAL OF CANCER
- Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
- (2019) Jacob H. Rasmussen et al. BRITISH JOURNAL OF CANCER
- Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer
- (2019) Angela M. Hong et al. ORAL ONCOLOGY
- TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2
- (2019) Paramita Baruah et al. Frontiers in Immunology
- Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
- (2019) Barbara Burtness et al. JAMA Oncology
- Interferon β and Anti-PD-1/PD-L1 Checkpoint Blockade Cooperate in NK Cell-Mediated Killing of Nasopharyngeal Carcinoma Cells
- (2019) Anna Makowska et al. Translational Oncology
- Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma
- (2019) Lei Wu et al. Cancer Immunology Research
- Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization
- (2019) Nai-Yun Sun et al. Cancers
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma
- (2019) Jian Wang et al. Scientific Reports
- Targeting CMTM6 suppresses stem cell-like properties and enhances antitumor immunity in head and neck squamous cell carcinoma
- (2019) Lei Chen et al. Cancer Immunology Research
- Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients
- (2019) Qinchuan Wang et al. Journal for ImmunoTherapy of Cancer
- Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
- (2019) Paul Buderath et al. Frontiers in Oncology
- Transforming growth factor beta induces fibroblasts to express and release the immunomodulatory protein PD‐L1 into extracellular vesicles
- (2019) Jeong‐Han Kang et al. FASEB JOURNAL
- Immunotherapy for head and neck cancer: Recent advances and future directions
- (2019) John D. Cramer et al. ORAL ONCOLOGY
- Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians
- (2018) Sophie Outh-Gauer et al. CANCER TREATMENT REVIEWS
- Separation of plasma-derived exosomes into CD3(+) and CD3(-) fractions allows for association of immune cell and tumour cell markers with disease activity in HNSCC patients
- (2018) M.-N. Theodoraki et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Novel effector phenotype of Tim-3+ regulatory T cells leads to enhanced suppressive function in head and neck cancer patients
- (2018) Zhuqing Liu et al. CLINICAL CANCER RESEARCH
- Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine
- (2018) Yee Sun Tan et al. CLINICAL CANCER RESEARCH
- Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma
- (2018) Jonathan D. Schoenfeld et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
- (2018) Robert L. Ferris et al. ORAL ONCOLOGY
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments
- (2018) Benjamin Solomon et al. SEMINARS IN CANCER BIOLOGY
- Immunotherapy in head and neck cancer – scientific rationale, current treatment options and future directions
- (2018) SWISS MEDICAL WEEKLY
- Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
- (2018) Genevieve P Hartley et al. Cancer Immunology Research
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Exosomes in HNSCC plasma as surrogate markers of tumour progression and immune competence
- (2018) M.-N. Theodoraki et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis
- (2018) Wei-fa Yang et al. ORAL ONCOLOGY
- Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma
- (2018) Seong-Ho Kang et al. OncoImmunology
- Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer
- (2018) Erminia Massarelli et al. JAMA Oncology
- Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
- (2018) M Oliva et al. ANNALS OF ONCOLOGY
- Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
- (2018) Dan P. Zandberg et al. EUROPEAN JOURNAL OF CANCER
- Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnea patients
- (2018) Carolina Cubillos-Zapata et al. EUROPEAN RESPIRATORY JOURNAL
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients
- (2018) Fernando Concha-Benavente et al. Cancer Immunology Research
- Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
- (2018) Lillian L. Siu et al. JAMA Oncology
- Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages
- (2017) Canhua Jiang et al. IMMUNOBIOLOGY
- The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
- (2017) Panagiotis Balermpas et al. INTERNATIONAL JOURNAL OF CANCER
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
- (2017) Joshua Bauml et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive T-cell immunophenotyping and next-generation sequencing of human papillomavirus (HPV)-positive and HPV-negative head and neck squamous cell carcinomas
- (2017) Kate Poropatich et al. JOURNAL OF PATHOLOGY
- Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
- (2017) Riccardo Mezzadra et al. NATURE
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
- (2017) Marian L. Burr et al. NATURE
- Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
- (2017) Axel Lechner et al. Oncotarget
- Increased PD-1 + and TIM-3 + TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients
- (2017) Hyun-Bae Jie et al. Cancer Immunology Research
- Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
- (2017) Linda Tran et al. Cancer Immunology Research
- Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy
- (2017) Dan Ou et al. OncoImmunology
- Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment
- (2017) Corinne Levingston et al. Cancers
- CD163+CD204+ tumor-associated macrophages contribute to T cell regulation via interleukin-10 and PD-L1 production in oral squamous cell carcinoma
- (2017) Keigo Kubota et al. Scientific Reports
- Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research
- (2016) K. A. Schalper et al. CLINICAL CANCER RESEARCH
- CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1
- (2016) Y. Lee et al. CLINICAL CANCER RESEARCH
- Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment
- (2016) Mariko Hirai et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Exosomes and tumor-mediated immune suppression
- (2016) Theresa L. Whiteside JOURNAL OF CLINICAL INVESTIGATION
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials
- (2016) Angela M Hong et al. Oncotarget
- Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
- (2016) Hae Su Kim et al. Cancer Research and Treatment
- Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
- (2016) Gulidanna Shayan et al. OncoImmunology
- Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk
- (2016) Jing Li et al. OncoImmunology
- PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
- (2016) Hye Ryun Kim et al. Scientific Reports
- Oral cavity and oropharyngeal squamous cell carcinoma-an update
- (2015) Angela C. Chi et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression
- (2015) A E Rice et al. CANCER GENE THERAPY
- Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma
- (2015) M. Vassilakopoulou et al. CLINICAL CANCER RESEARCH
- Immunology and Immunotherapy of Head and Neck Cancer
- (2015) Robert L. Ferris JOURNAL OF CLINICAL ONCOLOGY
- Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma
- (2015) Patcharee Ritprajak et al. ORAL ONCOLOGY
- PD-L1 Blockade for Cancer Treatment: MEDI4736
- (2015) Ramy Ibrahim et al. SEMINARS IN ONCOLOGY
- PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma
- (2015) Guang-Tao Yu et al. Oncotarget
- Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma
- (2015) Simona Partlová et al. OncoImmunology
- High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma
- (2015) Yueh-Min Lin et al. PLoS One
- Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression
- (2014) Chunxiao Xu et al. CANCER CELL
- Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma
- (2014) Ian-James Malm et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients
- (2013) H-B Jie et al. BRITISH JOURNAL OF CANCER
- Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
- (2013) S. Lyford-Pike et al. CANCER RESEARCH
- Promising New Molecular Targeted Therapies in Head and Neck Cancer
- (2013) Kelly Dorsey et al. DRUGS
- PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
- (2012) C. Badoual et al. CANCER RESEARCH
- The Immune Signature of CD8+CCR7+ T Cells in the Peripheral Circulation Associates with Disease Recurrence in Patients with HNSCC
- (2012) M. Czystowska et al. CLINICAL CANCER RESEARCH
- Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway
- (2011) Jiao Chen et al. IMMUNOBIOLOGY
- PD-L2 is expressed on activated human T cells and regulates their function
- (2011) Nassima Messal et al. MOLECULAR IMMUNOLOGY
- Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma
- (2011) Young-Ah Cho et al. ORAL ONCOLOGY
- B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
- (2010) J.-J. Park et al. BLOOD
- Macrophages, innate immunity and cancer: balance, tolerance, and diversity
- (2010) Alberto Mantovani et al. CURRENT OPINION IN IMMUNOLOGY
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma
- (2010) Mei-Chi Hsu et al. MODERN PATHOLOGY
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
- (2008) Shawn D Blackburn et al. NATURE IMMUNOLOGY
- Recent Advances in Head and Neck Cancer
- (2008) Robert I. Haddad et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started